Navigation Links
Cure for cancer worth $50 trillion

A new study, to be published in a forthcoming issue of the Journal of Political Economy, calculates the prospective gains that could be obtained from further progress against major diseases. Kevin M. Murphy and Robert H. Topel, two University of Chicago researchers, estimate that even modest advancements against major diseases would have a significant impact ?a 1 percent reduction in mortality from cancer has a value to Americans of nearly $500 billion. A cure for cancer would be worth about $50 trillion.

"We distinguish two types of health improvements ?those that extend life and those that raise the quality of life," explain the authors. "As the population grows, as incomes grow, and as the baby-boom generation approaches the primary ages of disease-related death, the social value of improvements in health will continue to rise."

Many critiques of rising medical expenditures focus on life-extending procedures for persons near death. By breaking down net gains by age and gender, Murphy and Topel show that the value of increased longevity far exceeds rising medical expenditures overall. Gains in life expectancy over the last century were worth about $1.2 million per person to the current population, with the largest gains at birth and young age.

"An analysis of the value of health improvements is a first step toward evaluating the social returns to medical research and health-augmenting innovations," write the authors. "Improvements in life expectancy raise willingness to pay for further health improvements by increasing the value of remaining life."

Murphy and Topel also chart individual values resulting from the permanent reduction in mortality in several major diseases ?including heart disease, cancer, and diabetes. Overall, reductions in mortality from 1970 to 2000 had an economic value to the U.S. population of $3.2 trillion per year.


'"/>

Source:University of Chicago Press Journals


Page: 1

Related biology news :

1. Viral DNA sequence a possible trigger for breast cancer
2. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
3. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
4. Columbia research lifts major hurdle to gene therapy for cancer
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Mitochondrial DNA mutations play significant role in prostate cancer
7. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
8. BRCA1 causes ovarian cancer through indirect, biochemical route
9. Researchers identify target for cancer drugs
10. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
11. First atlas of key brain genes could speed research on cancer, neurological diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... research organization (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for ... a 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs ...
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg ... Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads ... eye drops in a group of 20 patients carrying 11778, 14484 and 3460 mutations ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... flow controllers based on capillary thermal mass flow technology provide exponentially more accurate ... applications. Over 80% of all industrial processes—such as those involving chemical reactions, ...
(Date:4/27/2017)...  Pendant Biosciences, Inc. (formerly Nanoferix, Inc.), a privately-held ... delivery technologies, today announced that it has been accepted ... Toronto . Shawn Glinter , ... "We are excited to become part of the JLABS ... honored to be the first Tennessee ...
Breaking Biology Technology: